237 related articles for article (PubMed ID: 32801295)
1. Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance.
Alcon C; Manzano-Muñoz A; Prada E; Mora J; Soriano A; Guillén G; Gallego S; Roma J; Samitier J; Villanueva A; Montero J
Cell Death Dis; 2020 Aug; 11(8):634. PubMed ID: 32801295
[TBL] [Abstract][Full Text] [Related]
2. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
Alcon C; Gómez Tejeda Zañudo J; Albert R; Wagle N; Scaltriti M; Letai A; Samitier J; Montero J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359829
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
4. Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells.
Erdogdu U; Dolgikh N; Laszig S; Särchen V; Meister MT; Wanior M; Knapp S; Boedicker C
Neoplasia; 2022 Feb; 24(2):109-119. PubMed ID: 34959030
[TBL] [Abstract][Full Text] [Related]
5. BCL-x
Faqar-Uz-Zaman SF; Heinicke U; Meister MT; Vogler M; Fulda S
Cancer Lett; 2018 Jan; 412():131-142. PubMed ID: 28947136
[TBL] [Abstract][Full Text] [Related]
6. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Bhatt S; Pioso MS; Olesinski EA; Yilma B; Ryan JA; Mashaka T; Leutz B; Adamia S; Zhu H; Kuang Y; Mogili A; Louissaint A; Bohl SR; Kim AS; Mehta AK; Sanghavi S; Wang Y; Morris E; Halilovic E; Paweletz CP; Weinstock DM; Garcia JS; Letai A
Cancer Cell; 2020 Dec; 38(6):872-890.e6. PubMed ID: 33217342
[TBL] [Abstract][Full Text] [Related]
7. Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations.
Henz K; Al-Zebeeby A; Basoglu M; Fulda S; Cohen GM; Varadarajan S; Vogler M
Biol Chem; 2019 Jan; 400(2):181-185. PubMed ID: 29924730
[TBL] [Abstract][Full Text] [Related]
8. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
9. A direct comparison of selective BH3-mimetics reveals BCL-X
Bierbrauer A; Jacob M; Vogler M; Fulda S
Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
[TBL] [Abstract][Full Text] [Related]
10. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
11. JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis.
Heinicke U; Kupka J; Fulda S
Oncotarget; 2015 Nov; 6(35):37836-51. PubMed ID: 26473375
[TBL] [Abstract][Full Text] [Related]
12. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
13. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x
Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429
[TBL] [Abstract][Full Text] [Related]
14. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
[TBL] [Abstract][Full Text] [Related]
15. Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X
Kehr S; Haydn T; Bierbrauer A; Irmer B; Vogler M; Fulda S
Cancer Lett; 2020 Jul; 482():19-32. PubMed ID: 32145345
[TBL] [Abstract][Full Text] [Related]
16. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
17. A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors.
Manzella G; Moonamale DC; Römmele M; Bode P; Wachtel M; Schäfer BW
Neoplasia; 2021 Sep; 23(9):929-938. PubMed ID: 34329950
[TBL] [Abstract][Full Text] [Related]
18. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling.
Surman DR; Xu Y; Lee MJ; Trepel J; Brown K; Ramineni M; Splawn TG; Diggs LP; Hodges HC; Davis JL; Lee HS; Burt BM; Ripley RT
Mol Cancer Ther; 2021 Aug; 20(8):1469-1480. PubMed ID: 34088830
[TBL] [Abstract][Full Text] [Related]
20. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X
Yasuda Y; Ozasa H; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Tsuji T; Yoshida H; Sakamori Y; Nakajima N; Menju T; Yoshizawa A; Date H; Hirai T
Cell Death Dis; 2020 Mar; 11(3):177. PubMed ID: 32152266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
